Impedimed Limited · ASX:IPD

Impedimed — Wilsons Advisory Drug & Device Conference 2024

12 slides from Impedimed's conference presentation, Oct 24, 2024

  1. Slide 1: Presentation – Wilsons Advisory Drug & Device Conference

    ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 24 October 2024 For personal use only Companies Announcements Office Australian Securities Exchange Presentation – Wilsons Advisory Drug & Device Conference ImpediMed Limited (ASX:I

  2. Slide 2: Forging a new Standard of Care

    For personal use only ImpediMed Limited Forging a new Standard of Care Wilsons Advisory Drug & Device Conference, 2024 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 1

  3. Slide 3: Forward Looking Statements

    Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, For personal use only assumptions and expectations and on information currently available to management. All statements that address o

  4. Slide 4: SOZO Digital Health Platform with Multiple FDA Cleared Applications

    SOZO® Digital Health Platform with Multiple FDA For personal use only One device, multiple FDA Cleared Applications cleared applications with Primary Focus on Breast • Lymphoedema – FDA clearance, CE Mark Cancer Related Lymphoedema • Body composition – FDA (BCRL) Prevention clearance, CE Mark • Hear

  5. Slide 5: Improving Survivorship for US Breast Cancer Patients

    Improving Survivorship for 310k 82% For personal use only Newly diagnosed US breast Breast cancer patients are at US Breast Cancer cancer patients every year1 • There are 4+ million breast risk of arm lymphedema due to their treatment5 cancer survivors1 • Lymph node surgery​ Patients • Radiation the

  6. Slide 6: SOZO BIS: Critical elements in place to forge the new Standard of Care

    SOZO® BIS: Critical elements in place to forge the new Standard of Care to capture $600M BCRL TAM For personal use only Positive Global Clinical Trial Widespread and Increasing US Payor 1200 patient trial: Statistically Significant FDA cleared Coverage Lower Progression to Chronic Lymphoedema1 appli

  7. Slide 7: BIS technology replaces time consuming SOC with early, objective & fast detection

    ImpediMed’s Bioimpedance Spectroscopy (BIS) technology replaces time consuming SOC with early, objective & fast detection technology Current Standard of Care (SOC) Bioimpedance Spectroscopy (BIS) – FDA-cleared, Clinically Validated, For personal use only Subjective or Time-Consuming Guideline Suppor

  8. Slide 8: SAAS Business with growing Global Installed Base and Annual Recurring Revenue

    SAAS Business with growing Global Installed Base and Annual Recurring Revenue For personal use only Global Installed Base SOZO Annual Recurring Revenue1 ROW Installed Base Units US Installed base A$ millions • Low churn, 3% annualized • ARR up 21% vs Q1 FY24 1.Annual Recurring Revenue (ARR) represen

  9. Slide 9: Financial momentum continues with record quarterly increase in TCV

    Financial momentum continues with record quarterly increase in TCV1 Q1 FY25 Financial Highlights SOZO Core Business Quarterly TCV For personal use only # SOZO units SOZO Core sold U.S. Business TCV 28 $4.8 million1 22% vs Q4 FY24 40% vs Q4 FY24 Total SOZO Core revenue Business ARR • 6 networks contr

  10. Slide 10: Key forward looking metrics improving

    Key forward looking metrics improving Q1 FY25 Metrics For personal use only Covered Lives1 Opportunity Pipeline Units 146.6M 585 5% vs Q4 FY24 34% increase vs Q4 FY24 3 additional payors providing coverage 1 new NCCN Center 16 States now at Critical Mass2 SOZO at 23/33 19 Private payors providing po

  11. Slide 11: Immediate priority is focused sales, marketing and clinical execution in BCRL

    Immediate priority is focused sales, marketing and clinical execution in BCRL, with 2-year strategy looking at adjacent markets ImpediMed 12-Month Priorities For personal use only Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOA

  12. Slide 12: Building a sustainable business

    Building a sustainable business For personal use only New Executive Team and new Board Expanded commercial focus on lead generation for targeted US BCRL customers More efficient cost management Building a pathway to future growth

ImpediMed — Wilsons Advisory Drug & Device Conference 2024 on 6ix